Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
10/13/2021 | $12.00 | Buy | Brookline Capital | |
6/29/2021 | $5.00 | Buy | Litchfield Hills |
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
HANGZHOU, China, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the six months ended June 30, 2024 before the U.S. market opens on Wednesday, September 18, 2024. The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on September 18, 2024. For participants who wish to join the call, please access the link provided below to complete the online registration process. Registration Link: https://s1.c-
HANGZHOU, China, March 18, 2024 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of December 31, 2023 and for the six months ended December 31, 2023 Second Half of 2023 Financial Highlights Net revenue was RMB26.1 million (US$3.7 million) for the second half of 2023, compared to RMB603.0 million in the same period of 2022.Gross loss was RMB40.6 million (US$5.7 million) for the second half of 2023, compared to a gross profit of RMB53.8 million in the same period of 2022.Loss from operations was RMB124 million (US
HANGZHOU, China, March 11, 2024 /PRNewswire/ -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the six months ended December 31, 2023 before the U.S. market opens on Monday, March 18, 2024. The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on March 18, 2024. For participants who wish to join the call, please access
SC 13D/A - Nano Labs Ltd (0001872302) (Subject)
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00
U.S. stocks traded slightly higher toward the end of trading, with the Dow Jones gaining by more than 50 points on Tuesday. The Dow traded up 0.17% to 40,483.92 while the NASDAQ rose 0.20% to 18,043.64. The S&P 500 also rose, gaining, 0.14% to 5,572.07. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline Coca-Cola Company (NYSE:KO) reported better-than-expected second-quarter results and raised its guidance. The company reported second-quarter FY24 sales growth of 3% year-on-year to $12.4
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday. The Dow traded up 0.09% to 40,452.70 while the NASDAQ rose 0.62% to 18,119.84. The S&P 500 also rose, gaining, 0.32% to 5,582.32. Check This Out: How To Earn $500 A Month From Alphabet Stock Ahead Of Q2 Earnings Report Leading and Lagging SectorsConsumer discretionary shares jumped by 1% on Tuesday. In trading on Tuesday, energy shares fell by 1.4%. Top Headline GE Aerospace (NYSE:GE) reported better-than-expected second-quarter earnings and raised its FY24 outlook. GE Aerospace reported second-quarter 2024 adjusted revenue growth of 4% year-over-year to
HANGZHOU, China, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the six months ended June 30, 2024 before the U.S. market opens on Wednesday, September 18, 2024. The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on September 18, 2024. For participants who wish to join the call, please access the link provided below to complete the online registration process. Registration Link: https://s1.c-
GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York City. Adial's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024 at 7:00 AM Eastern Time. A webcast of the Company's
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. Significant Global Licensing Agreements: - Vitargus® Licensing: Along with
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "Throughout 2023 we
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating Officer. A highly accomplished pharmaceutical industry executive and member of Adial's Board of Directors since 2017, Mr. Goodman will oversee the Company's strategic growth initiatives, including clinical development and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the area
HANGZHOU, China, Dec. 1, 2023 /PRNewswire/ -- Nano Labs Ltd (NASDAQ:NA) ("we," "the Company," or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, announced today the results of the Company's 2023 Annual General Meeting of Shareholders ("2023 AGM") held on December 1, 2023, at 10:00 a.m. China Standard Time in Beijing, China. The proposal submitted for shareholder approval at the 2023 AGM has been approved. Specifically, the shareholders have passed resolution approving the ratification of the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)